ExeGi Pharma, The makers of Visbiome Vet is focused on research and development of microbiome science and expanding the use of the De Simone Formulation contained in Visbiome® Vet in a variety of therapeutic areas. ExeGi Pharma currently has five clinical trials ongoing in additional gastrointestinal conditions of both dogs and cats.
| Disease State | Primary Endpoint | Sponsor/Collaborator | Trial Design | Estimated Enrollment |
|---|---|---|---|---|
| CKD in cats | Reduction of serum indoxyl sulfate conc. and preservation of renal function | Midwestern University | Pilot trial | TBD |
| Intestinal inflammation and fecal dysbiosis | Canine Esomeprazole/Probiotic study (effect of probiotic admin. on fecal dysbiosis and intestinal inflam. Secondary to Esomeprazole admin in healthy dogs) | University of Wisconsin | Prospective, sequential study | 14 |
| Hepatic Encephalopathy | HE clinical signs and blood ammonia levels | University of Georgia | Control vs Metronidazole | 20 |
| Canine Epilepsy | Effect of probiotic on seizure frequency and microbiome in idiopathic epilepsy receiving anti-epileptic drugs | University of Wisconsin | Placebo-controlled, double-blinded, cross-over | 30 |
| Chronic Intermittent Diarrhea/evaluation of microbiome and fecal consistency in captive gibbons | Evaluate changes to the microbiome and fecal consistency over time after probiotic treatment and identify taxa that may be involved in chronic intermittent diarrhea in captive gibbons | Gibbon Conservation Center | Multi-year study | 37 |
If you are interested in conducting studies with Visbiome® Vet,
Let us know by filling out a short form
